Physician profile
Edgar B Jackson
NPI 1598833410
$4,792.26
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,080 · 2021: $909 · 2022: $407 · 2023: $472 · 2024: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,031.67 | 2019-2023 | Hetlioz, Fanapt |
| Allergan, INC. | $687.77 | 2019-2020 | |
| Lundbeck LLC | $524.58 | 2019-2024 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $448.73 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $403.05 | 2021-2024 | |
| Alkermes, INC. | $268.86 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.67 | 2021-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $208.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $207.65 | 2019-2024 | Invega Sustenna |
| Indivior INC. | $135.20 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $120.40 | 2022-2024 | Austedo Xr, Uzedy |
| Almatica Pharma LLC | $119.57 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $84.50 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $78.79 | 2019-2021 | |
| Axsome Therapeutics, INC. | $52.77 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.51 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.03 | 2022 | |
| Eisai INC. | $20.15 | 2021 | |
| Shire North American Group INC | $19.04 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.30 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.99 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.